Sign up
Pharma Capital

Clinigen Group appoints Nick Keher as new CFO

Keher has previously headed up Royal Bank of Canada’s European healthcare equity research team, while he has also held roles at GSK and Lloyd’s Pharmacy
pills
Keher is replacing Martin Abell, who has been Clinigen’s CFO since 2015

Pharma services company Clinigen Group PLC (LON:CLIN) has appointed Nick Keher as its new chief financial officer.

Keher, who is set to take up his new role on 19 March, joins from Canadian investment bank Royal Bank of Canada, where he was a managing director and head of the European healthcare equity research team.

READ: Clinigen to report sharp jump in revenue and profit

He is replacing the outgoing Martin Abell who has resigned and is due to leave a couple of weeks after Keher’s arrival.

“Nick brings considerable pharmacy and pharmaceutical experience as well as financial expertise, both as an accountant and from working in the financial markets,” said chief executive Shaun Chilton.

“He has a deep knowledge and insight of our business through his research and analysis of Clinigen since its IPO in 2012. He will be a key addition to the executive management team.”

Clinigen shares were down 2.1% to 794p in late morning trading on Tuesday.

View full CLIN profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.